<DOC>
	<DOC>NCT00930501</DOC>
	<brief_summary>young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.</brief_summary>
	<brief_title>Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients</brief_title>
	<detailed_description>our objective is to prospectively follow patients before and after their cancer treatment. this should help us learn of the gonadotoxicity of various treatments as well as be able to better consult these and future patients of the need of fertility preservation techniques.</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<criteria>all females prior and after chemotherapy do not consent</criteria>
	<gender>Female</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>cancer</keyword>
	<keyword>AMH</keyword>
	<keyword>gonadotoxicity</keyword>
	<keyword>ovarian reserve</keyword>
	<keyword>patients exposed to chemotherapy</keyword>
</DOC>